Tolerability of Red Yeast Rice (2,400 mg Twice Daily) Versus Pravastatin (20 mg Twice Daily) in Patients With Previous Statin Intolerance
November 30th, 2009 Posted by: admin
Publication year: 2009
Source: The American Journal of Cardiology, In Press, Corrected Proof, Available online 26 November 2009
Steven C., Halbert , Benjamin, French , Ram Y., Gordon , John T., Farrar , Kathryn, Schmitz , …
Currently, no consensus has been reached regarding the management of hyperlipidemia in patients who develop statin-associated myalgia (SAM). Many statin-intolerant patients use alternative lipid-lowering therapies, including red yeast rice. The present trial evaluated the tolerability of red yeast rice versus pravastatin in patients unable to tolerate other statins because of myalgia. The study was conducted in a community-based setting in Philadelphia, Pennsylvania. A total of 43 adults with dyslipidemia and a history of statin discontinuation because of myalgia were randomly assigned to red yeast rice 2,400 mg twice daily or pravastatin 20 mg twice daily for 12 weeks. All subjects…
Similar Posts:
- Lipid-Lowering Efficacy of Red Yeast Rice in a Population Intolerant to Statins
- Red Yeast Rice Supplement May Be Option for Dyslipidemia (CME/CE)
- Red Yeast Rice Supplement May Be Option for Dyslipidemia (CME/CE)
- Statin treatment after a recent TIA or stroke: is effectiveness shown in randomized clinical trials also observed in everyday clinical practice?
- Safety and Tolerability of Donepezil in Mild Cognitive Impairment: Open-Label Extension Study
- Eligibility for Statin Therapy by the JUPITER Trial Criteria and Subsequent Mortality
- Effect of Baseline Glycemic Level on Long-Term Cardiovascular Outcomes After Coronary Revascularization Therapy in Patients With Type 2 Diabetes Mellitus Treated With Hypoglycemic Agents
- Effect of Baseline Glycemic Level on Long-Term Cardiovascular Outcomes After Coronary Revascularization Therapy in Patients With Type 2 Diabetes Mellitus Treated With Hypoglycemic Agents
- Poor tolerability of high dose ascorbic acid in a population of genetically confirmed adult Charcot-Marie-Tooth 1A patients
- Effect of Pravastatin Therapy on Coronary Events in Carriers of the KIF6 719Arg Allele from the Cholesterol and Recurrent Events Trial